➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Johnson and Johnson
Harvard Business School
Dow
AstraZeneca
Moodys

Last Updated: October 1, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,821,927

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,821,927 protect, and when does it expire?

Patent 8,821,927 protects TYKERB and is included in one NDA.

This patent has twenty-nine patent family members in twenty-seven countries.

Summary for Patent: 8,821,927
Title:Pharmaceutical composition
Abstract: Oral pharmaceutical formulations containing ditosylate salts of 4-quinazolineamines are described as well as methods of using the same in the treatment of disorders characterized by aberrant erbB family PTK activity.
Inventor(s): Carter; Barry Howard (Kinston, NC), Campbell; Dwayne A (Durham, NC)
Assignee: SmithKline Beecham (Cork) Limited (Carrigaline, County Cork, IE)
Application Number:11/911,843
Patent Claim Types:
see list of patent claims
Formulation; Compound; Dosage form; Process;

Drugs Protected by US Patent 8,821,927

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Novartis TYKERB lapatinib ditosylate TABLET;ORAL 022059-001 Mar 13, 2007 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,821,927

PCT Information
PCT FiledApril 18, 2006PCT Application Number:PCT/US2006/014447
PCT Publication Date:October 26, 2006PCT Publication Number: WO2006/113649

International Family Members for US Patent 8,821,927

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 054252   Start Trial
Australia 2006236423   Start Trial
Brazil PI0609962   Start Trial
Canada 2606207   Start Trial
China 101203211   Start Trial
Cyprus 1118179   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Moodys
Colorcon
Dow
Harvard Business School
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.